The development of Canada’s exclusivity framework was the focus of a roundtable at Life Sciences Patent Network North America, hosted by LSPR in Boston.
Daphne Lainson, partner at Smart & Biggar/Fetherstonhaugh, discussed the upcoming changes to introduce a patent term extension, something that the country has never had before.
In May, the Senate of Canada passed Bill C-30, which will change Canada’s pharma patent regulations.
The bill, which will implement the Canada-European Union Comprehensive Economic and Trade Agreement, was given royal assent on May 16.
Lainson also discussed changes in linkage litigation—“which could very significantly alter the way in which patent litigation is conducted in Canada for pharmaceuticals”.
To find out more, you can watch the video below.